Q-omics provides the consensus-scored KLF13 profile across patient tissues and cancer cell-line models. KLF13 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KLF13 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, KLF13 RNA expression shows 19,966 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where KLF13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLF13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLF13 survival associations across molecular data types. KLF13 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLF13 RNA expression–survival associations across cancer types. High KLF13 expression shows unfavorable associations in BLCA, ACC and THCA, but favorable associations in KIRC, UCS and THYM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KLF13 RNA expression.
This table summarizes KLF13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for KLF13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLF13 shows lower tumor expression in BLCA, LUAD and THCA and higher tumor expression in HNSC, LIHC and STAD. The HNSC box plot shows higher KLF13 RNA expression in tumor versus normal tissue (log2 FC = +1.174, t-test p < 0.001).
This table shows molecular features associated with KLF13 in patient tissues and cancer cell lines. In patient samples, KLF13 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, KLF13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
